VACC RSI Chart
Last 7 days
-4.6%
Last 30 days
11.8%
Last 90 days
3.8%
Trailing 12 Months
49.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 33.7M | 22.8M | 11.8M | 802.0K |
2022 | 18.3M | 27.1M | 35.9M | 44.7M |
2021 | 4.3M | 3.9M | 623.0K | 9.4M |
2020 | 0 | 0 | 0 | 4.8M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 26, 2023 | scheeren joseph | bought | 24,400 | 2.44 | 10,000 | - |
May 25, 2023 | wright robin | bought | 36,612 | 2.6627 | 13,750 | - |
Mar 27, 2023 | enright william | sold | -36,298 | 2.4199 | -15,000 | chief executive officer |
Sep 30, 2022 | m&g alternatives investment management ltd | sold | - | - | -4,108,750 | - |
Sep 30, 2022 | m&g investment management ltd | acquired | - | - | 4,108,750 | - |
Aug 25, 2022 | ellis christopher | acquired | 15.6704 | 0.0004 | 39,176 | chief operating officer |
Aug 25, 2022 | ellis christopher | sold | -257,396 | 6.57024 | -39,176 | chief operating officer |
Aug 25, 2022 | griffiths graham | sold | -73,870 | 7.387 | -10,000 | chief business officer |
Aug 24, 2022 | ellis christopher | acquired | 0.18 | 0.0004 | 450 | chief operating officer |
Aug 24, 2022 | ellis christopher | sold | -2,152 | 4.7827 | -450 | chief operating officer |
Which funds bought or sold VACC recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | Janney Montgomery Scott LLC | unchanged | - | -19,000 | 36,000 | -% |
Apr 19, 2024 | Ipswich Investment Management Co., Inc. | unchanged | - | -30,228 | 54,919 | 0.01% |
Feb 14, 2024 | Johns Hopkins University | unchanged | - | 64,000 | 398,000 | 0.02% |
Feb 14, 2024 | Baird Financial Group, Inc. | unchanged | - | 117,777 | 724,332 | -% |
Feb 14, 2024 | BlueCrest Capital Management Ltd | unchanged | - | 325,603 | 2,002,460 | 0.08% |
Feb 14, 2024 | HSG Holding Ltd | unchanged | - | -85,229 | 4,304,030 | 0.50% |
Feb 14, 2024 | Royal Bank of Canada | sold off | -100 | -3,000 | - | -% |
Feb 13, 2024 | MORGAN STANLEY | reduced | -22.38 | -4,791 | 60,763 | -% |
Feb 13, 2024 | DC Funds, LP | unchanged | - | 385,323 | 2,369,730 | 28.49% |
Unveiling Vaccitech plc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Vaccitech plc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.1B | 6.8B | -8.06 | 7.03 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.0B | 2.0B | -57.25 | 9.49 | ||||
BMRN | 15.9B | 2.5B | 77.41 | 6.43 | ||||
INCY | 11.9B | 3.8B | 15.99 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.83 | 14.44 | ||||
BBIO | 5.2B | 107.9M | -9.5 | 48.09 | ||||
AXSM | 3.5B | 270.6M | -14.69 | 12.99 | ||||
ARWR | 3.0B | 240.7M | -10.07 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.92 | 3.87 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.79 | 4.45 | ||||
NVAX | 659.2M | 983.7M | -1.21 | 0.67 | ||||
CRBP | 400.8M | 881.7K | -8.99 | 466.16 | ||||
INO | 280.7M | 4.9M | -2.08 | 57.68 | ||||
IBIO | 7.0M | 2.1M | -0.26 | 2.14 |
Vaccitech plc News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | -100.0% | - | 167,000 | 334,000 | 3,395,500 | 6,457,000 | 6,165,000 | 17,063,000 | 15,018,000 | 7,518,500 | 19,000 | 35,000 | 215,000 | 354,000 | 3,251,000 | 511,000 | 705,000 |
Operating Expenses | 24.1% | 19,988,000 | 16,105,000 | 26,671,000 | 21,952,000 | 31,586,500 | -1,071,000 | 3,828,000 | 14,364,000 | 16,667,000 | 5,555,000 | 16,880,000 | 6,387,000 | 9,987,000 | 4,679,000 | 4,847,000 | 5,354,000 |
S&GA Expenses | - | - | - | - | 12,138,000 | - | - | - | 3,663,000 | 9,786,000 | 1,184,000 | 12,371,000 | 1,777,000 | 7,421,000 | 977,000 | 970,000 | 1,112,000 |
R&D Expenses | -57.9% | 6,373,000 | 15,144,000 | 13,543,000 | 9,814,000 | 12,185,000 | 9,744,000 | 9,720,000 | 10,701,000 | 6,881,000 | 4,371,000 | 4,509,000 | 4,610,000 | 2,566,000 | 3,702,000 | 3,877,000 | 4,242,000 |
EBITDA Margin | -1264.8% | -88.61 | -6.49 | -2.39 | -0.45 | 0.12 | -1.18 | -1.60 | -2.72 | -5.07 | - | - | - | - | - | - | - |
Interest Expenses | 800.0% | 49,000 | -7,000 | -14,000 | - | -21,500 | 11,000 | -7,000 | 74,000 | 5,318,000 | - | -5,300,000 | 2,650,000 | - | 969,000 | - | - |
Income Taxes | -36.0% | -820,000 | -603,000 | -1,136,000 | -516,000 | -2,019,000 | -674,000 | -915,000 | -863,000 | 32,000 | -7,000 | 12,000 | -65,000 | - | - | - | - |
Earnings Before Taxes | -23.1% | -18,110,000 | -14,713,000 | -24,960,000 | -18,739,000 | -23,182,000 | 7,547,000 | 14,774,000 | 1,711,000 | - | - | - | - | - | - | - | - |
EBT Margin | -1277.2% | -95.41 | -6.93 | -2.61 | -0.58 | 0.02 | -1.43 | -1.89 | -2.80 | -5.42 | - | - | - | - | - | - | - |
Net Income | -22.7% | -17,260,500 | -14,072,000 | -23,824,000 | -18,223,000 | -21,176,000 | 8,242,000 | 15,689,000 | 2,574,000 | -15,025,000 | -4,557,000 | -15,985,000 | -15,386,000 | -10,355,500 | 158,000 | -3,657,000 | -3,951,000 |
Net Income Margin | -1294.1% | -91.50 | -6.56 | -2.42 | -0.46 | 0.12 | 0.32 | -0.05 | -1.81 | -5.40 | -74.29 | -10.78 | -6.75 | -3.69 | - | - | - |
Free Cashflow | -73.2% | -19,450,000 | -11,227,000 | -19,980,000 | -5,681,000 | -11,929,000 | 9,478,000 | -10,447,000 | -7,671,000 | -8,396,000 | -2,146,000 | -14,826,000 | -8,361,000 | -5,091,000 | -891,000 | -996,000 | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -6.7% | 215 | 230 | 246 | 262 | 270 | 275 | 285 | 286 | 281 | 257 | 260 | 166 | 51.00 |
Current Assets | -8.3% | 157 | 171 | 185 | 201 | 213 | 219 | 226 | 231 | 227 | 246 | 257 | 163 | 48.00 |
Cash Equivalents | -11.4% | 142 | 160 | 173 | 191 | 194 | 200 | 192 | 201 | 214 | 234 | 244 | 156 | 43.00 |
Net PPE | -3.7% | 12.00 | 12.00 | 14.00 | 13.00 | 8.00 | 7.00 | 7.00 | 5.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Goodwill | 0% | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 13.00 | 13.00 | 13.00 | 13.00 | - | - | - | - |
Liabilities | -19.9% | 28.00 | 34.00 | 29.00 | 28.00 | 27.00 | 31.00 | 30.00 | 33.00 | 28.00 | 14.00 | 10.00 | 10.00 | 54.00 |
Current Liabilities | -32.2% | 13.00 | 19.00 | 12.00 | 12.00 | 12.00 | 14.00 | 12.00 | 16.00 | 11.00 | 6.00 | 9.00 | 9.00 | 8.00 |
Shareholder's Equity | -4.4% | 187 | 195 | 217 | 234 | 243 | 244 | 255 | 253 | 253 | 242 | 250 | - | - |
Retained Earnings | -10.9% | -176 | -159 | -145 | -121 | -103 | -82.05 | -90.30 | -105 | -108 | -93.47 | -88.91 | -72.99 | -57.72 |
Additional Paid-In Capital | 0.2% | 387 | 386 | 386 | 384 | 380 | 377 | 376 | 373 | 369 | 344 | 341 | 22.00 | 22.00 |
Shares Outstanding | 0.3% | 39.00 | 39.00 | 39.00 | 38.00 | 38.00 | 37.00 | 37.00 | 37.00 | 37.00 | 35.00 | 17.00 | 8.00 | 8.00 |
Minority Interest | 2.9% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
Float | - | - | - | 79.00 | - | - | - | 166 | - | - | - | 404 | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -75.2% | -19,603 | -11,191 | -16,957 | -3,174 | -11,343 | 11,884 | -8,393 | -6,579 | -7,972 | -2,018 | -14,624 | -7,969 | -4,896 | -861 | -950 | -4,321 |
Share Based Compensation | 1278.9% | 786 | 57.00 | 1,990 | 2,222 | 2,041 | 1,104 | 2,748 | 3,984 | 3,580 | 3,374 | 8,736 | 797 | 2,200 | 154 | 415 | 856 |
Cashflow From Investing | 525.0% | 153 | -36.00 | -3,023 | -2,507 | -586 | -2,018 | -2,054 | -1,092 | -12,190 | -128 | -202 | -392 | -195 | -30.00 | -46.00 | -22.00 |
Cashflow From Financing | 137.0% | 109 | 46.00 | 28.00 | 1,689 | 484 | - | - | -159 | 9.00 | -1,387 | 102,305 | 121,815 | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |||
---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |||
Total revenue | $ 802 | $ 44,703 | ||
Operating expenses | ||||
Research and development | 44,874 | 42,350 | ||
General and administrative | 39,842 | 6,394 | ||
Total operating expenses | 84,716 | 48,744 | ||
Loss from operations | (83,914) | (4,041) | ||
Other income /(expense): | ||||
Interest income | 2,877 | 3,103 | ||
Interest expense | (28) | (19) | ||
Research and development incentives | 3,461 | 1,240 | ||
Other income, net | 1,082 | 567 | ||
Total other income, net | 7,392 | 4,891 | ||
(Loss)/profit before income tax | (76,522) | 850 | ||
Tax benefit | 3,075 | 4,471 | ||
Net (loss)/income | (73,447) | 5,321 | ||
Net loss attributable to noncontrolling interest | 100 | 21 | ||
Net (loss)/income attributable to Barinthus Biotherapeutics plc shareholders | $ (73,347) | $ 5,342 | ||
Weighted-average ordinary shares outstanding, basic (in shares) | 38,386,491 | 37,248,126 | ||
Weighted-average ordinary shares outstanding, diluted (in shares) | 38,386,491 | 38,169,307 | ||
Net (loss)/income per share attributable to ordinary shareholders, basic (in usd per share) | $ (1.91) | $ 0.14 | ||
Net (loss)/income per share attributable to ordinary shareholders, diluted (in usd per share) | $ (1.91) | $ 0.14 | ||
Net (loss)/income | $ (73,447) | $ 5,321 | ||
Other comprehensive gain/(loss) – foreign currency translation adjustments | 10,151 | (25,083) | ||
Comprehensive loss | (63,296) | (19,762) | ||
Comprehensive loss attributable to noncontrolling interest | 94 | 132 | ||
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders | (63,202) | (19,630) | ||
License revenue | ||||
Total revenue | [1] | 802 | 44,694 | |
Research grants and contracts | ||||
Total revenue | $ 0 | $ 9 | ||
|
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | |||
---|---|---|---|---|---|
ASSETS | |||||
Cash and cash equivalents | $ 142,090 | $ 194,385 | |||
Research and development incentives receivable | 4,908 | 4,541 | |||
Prepaid expenses and other current assets | 9,907 | 8,268 | |||
Total current assets | 156,905 | 213,041 | |||
Goodwill | 12,209 | 12,209 | |||
Property and equipment, net | 11,821 | 7,957 | |||
Intangible assets, net | 25,108 | 28,269 | |||
Right of use assets, net | 7,581 | 7,753 | |||
Other assets | 882 | 976 | |||
Total assets | 214,506 | 270,205 | |||
Current liabilities: | |||||
Accounts payable | 1,601 | 3,748 | |||
Accrued expenses and other current liabilities | 9,212 | 8,061 | |||
Operating lease liability - current | 1,785 | 433 | |||
Total current liabilities | 12,598 | 12,242 | |||
Non-Current liabilities: | |||||
Operating lease liability - non-current | 11,191 | 8,340 | |||
Contingent consideration | 1,823 | 1,711 | |||
Other non-current liabilities | 1,325 | 965 | |||
Deferred tax liability, net | 574 | 3,746 | |||
Total liabilities | 27,511 | 27,004 | |||
Commitments and contingencies (Note 16) | |||||
Stockholders’ equity: | |||||
Ordinary shares, £0.000025 nominal value; 38,643,540 shares authorized, issued and outstanding (December 31, 2022: authorized, issued and outstanding: 37,683,531) | 1 | 1 | |||
Additional paid-in capital | 386,602 | 379,504 | |||
Accumulated deficit | (176,590) | (103,243) | |||
Accumulated other comprehensive loss – foreign currency translation adjustments | (23,315) | (33,460) | |||
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders | 186,784 | 242,896 | |||
Noncontrolling interest | 211 | 305 | |||
Total stockholders’ equity | 186,995 | 243,201 | |||
Total liabilities and stockholders’ equity | 214,506 | 270,205 | |||
Deferred A shares | |||||
Stockholders’ equity: | |||||
Deferred shares | 86 | 86 | |||
Deferred B shares | |||||
Stockholders’ equity: | |||||
Deferred shares | 0 | 8 | |||
Deferred C shares | |||||
Stockholders’ equity: | |||||
Deferred shares | 0 | 0 | [1] | ||
Nonrelated parties | |||||
ASSETS | |||||
Accounts receivable | 0 | 323 | |||
Related parties | |||||
ASSETS | |||||
Accounts receivable | $ 0 | $ 5,524 | |||
|